- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years
June 1st 2019, 3:31pm
After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.
Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma
June 1st 2019, 5:28am
Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.
Dr. Agarwal on the TALAPRO-2 Trial in mCRPC
June 1st 2019, 4:43am
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.
ASCO 2019: Oncology Leaders Select Top Studies
May 29th 2019, 1:59am
Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.
Entrectinib Achieves Strong Responses in Pediatric Cancers, Including CNS Tumors
May 16th 2019, 1:34am
Entrectinib induced objective responses in 100% of pediatric patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions or mutations.
Pediatric Precision Medicine Approach Proven Possible in Pediatric MATCH Trial
May 16th 2019, 1:01am
About a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration of pathway in the screening protocol of the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial.
Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer
May 16th 2019, 1:00am
A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.
Lenalidomide Reduces Risk for Smoldering Multiple Myeloma Progression
May 16th 2019, 1:00am
In patients with smoldering multiple myeloma, lenalidomide induced a 72% reduction in the risk for progression to symptomatic disease at 3 years.
Low-Fat Diet Could Reduce Risk of Death From Breast Cancer
May 16th 2019, 12:59am
Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.
Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC
April 14th 2019, 3:05am
Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.
Dr. Reinmuth on Findings from the MYSTIC Study
April 13th 2019, 10:19pm
Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.
Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC
April 13th 2019, 9:53pm
James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.
Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC
April 13th 2019, 9:37pm
Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.
Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC
April 13th 2019, 9:28pm
No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.
Ramalingam Discusses Osimertinib Efficacy and the Journey to Overcome Acquired Resistance
April 12th 2019, 10:45pm
Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.
Update Further Supports Osimertinib in Frontline EGFR+ NSCLC
April 12th 2019, 10:10pm
Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non–small cell lung cancer.
Dr. Reck on the Rationale of the Impower150 Study
April 12th 2019, 9:02pm
Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.
Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC
April 12th 2019, 8:51pm
Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.
Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC
April 12th 2019, 12:19am
Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.
PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC
April 11th 2019, 9:07pm
Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.